Capricor Therapeutics is trading at $9.90, up 5.77%, extending a sharp multi-session rebound after the FDA moved deramiocel’s PDUFA deadline to November 22, 2026, allowing review of new HOPE-3 data and analyses.
- Oppenheimer upgraded the company to Outperform and set a $54 price target, reinforcing bullish sentiment.
- Broader risk-on trading, including a 1.15% Nasdaq gain, is providing additional support.